1 articles · Updated · reference.medscape.com · Jun 17
Summary
VLA15 has completed a Phase 3 trial, with the Lyme disease vaccine demonstrating efficacy and moving toward a planned regulatory filing.
The result marks a potential return of Lyme vaccination after the only previously licensed shot—approved in 1998 for people aged 15-70—was withdrawn in 2002 amid poor sales tied to safety concerns.
Lyme disease remains the most common vector-borne infection in the Northern Hemisphere, with about 30,000 U.S. cases reported annually, though a 2021 study estimated roughly 476,000 cases a year.
The need for new prevention tools is rising as tick habitats expand northward and to higher altitudes across North America and Europe, while many patients do not recall a tick bite.
Will a new seasonal antibody shot offer reliable Lyme protection, making tick bites less of a threat for 87 million Americans?
As climate change pushes ticks into new areas, are we prepared for a future where Lyme disease is a nationwide threat?
With standard tests failing 70% of the time, how can you reliably diagnose Lyme disease before it becomes a chronic condition?
VLA15 Lyme Disease Vaccine: 2026 Launch, Clinical Results, and the Future of Prevention
Overview
The VLA15 vaccine for Lyme disease is nearing regulatory approval and is expected to become publicly available in 2026. This progress is based on strong evidence from the VALOR trial, which demonstrated the vaccine’s efficacy and safety, forming the foundation for regulatory submissions. Although the trial faced challenges like fewer cases than expected and a reduced sample size, the overall data still show significant preventive potential. Overcoming earlier hurdles, VLA15 is now positioned to offer a much-needed tool for Lyme disease prevention, marking a major step forward in public health strategies.